| Title | State | Investigator/Sponsoring Organization |
|---|---|---|
| Familial and Atypical Urothelial Cancer Registry NCT ID: NCT00902590 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer NCT ID: NCT02324582 State: Multi-State Trial Investigator/Sponsoring Organization: Southern Illinois University |
Multi-State Trial | Southern Illinois University |
| Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Met... NCT ID: NCT02500121 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladde... NCT ID: NCT02625961 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-Interferon (IFN)/Syn3) Administered I... NCT ID: NCT02773849 State: Multi-State Trial Investigator/Sponsoring Organization: FKD Therapies Oy |
Multi-State Trial | FKD Therapies Oy |
| Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-... NCT ID: NCT02808143 State: Illinois Investigator/Sponsoring Organization: Northwestern University |
Illinois | Northwestern University |
| Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Ch... NCT ID: NCT02807636 State: Multi-State Trial Investigator/Sponsoring Organization: Hoffmann-La Roche |
Multi-State Trial | Hoffmann-La Roche |
| MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT ID: NCT02964013 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Uro... NCT ID: NCT03093922 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma NCT ID: NCT02793128 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Canc... NCT ID: NCT02643043 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Milowsky, MD |
Multi-State Trial | Matthew Milowsky, MD |
| Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in P... NCT ID: NCT03289962 State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc. |
Multi-State Trial | Genentech, Inc. |
| Safety and Preliminary Efficacy of NKTR 214 and Anti-PD-L1 (Atezolizumab) in Patients With Locally A... NCT ID: NCT03138889 State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics |
Multi-State Trial | Nektar Therapeutics |
| Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as... NCT ID: NCT02621151 State: Multi-State Trial Investigator/Sponsoring Organization: New York University School of Medicine |
Multi-State Trial | New York University School of Medicine |
| A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With ... NCT ID: NCT03519256 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasi... NCT ID: NCT02845323 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Maryland | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer W... NCT ID: NCT03558087 State: New York Investigator/Sponsoring Organization: Matthew Galsky |
New York | Matthew Galsky |
| A Phase 2b, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as a Chemoa... NCT ID: NCT03558503 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus ... NCT ID: NCT03661320 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/... NCT ID: NCT02091141 State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc. |
Multi-State Trial | Genentech, Inc. |
| Title | State | Investigator/Sponsoring Organization |
|---|---|---|
| Evaluation for NCI Surgery Branch Clinical Research Protocols NCT ID: NCT00001823 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients NCT ID: NCT00579514 State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
New York | Memorial Sloan Kettering Cancer Center |
| Prophylactic Cranial Irradiation (PCI) for Patients With Small Cell Carcinoma of the Urothelium NCT ID: NCT00756639 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney NCT ID: NCT00872495 State: Massachusetts Investigator/Sponsoring Organization: Lahey Clinic |
Massachusetts | Lahey Clinic |
| Familial and Atypical Urothelial Cancer Registry NCT ID: NCT00902590 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) NCT ID: NCT00978250 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy NCT ID: NCT01776138 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy NCT ID: NCT01050504 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemot... NCT ID: NCT00981656 State: Multi-State Trial Investigator/Sponsoring Organization: Radiation Therapy Oncology Group |
Multi-State Trial | Radiation Therapy Oncology Group |
| Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Perfo... NCT ID: NCT01224665 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tra... NCT ID: NCT01261728 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Dose Escalation Study of MGA271 in Refractory Cancer NCT ID: NCT01391143 State: Multi-State Trial Investigator/Sponsoring Organization: MacroGenics |
Multi-State Trial | MacroGenics |
| Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers NCT ID: NCT01631552 State: Multi-State Trial Investigator/Sponsoring Organization: Immunomedics, Inc. |
Multi-State Trial | Immunomedics, Inc. |
| PK Button Vaporization Electrode for Treatment of Bladder Tumors NCT ID: NCT01567462 State: Georgia Investigator/Sponsoring Organization: Emory University |
Georgia | Emory University |
| Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the... NCT ID: NCT01489813 State: Multi-State Trial Investigator/Sponsoring Organization: Emory University |
Multi-State Trial | Emory University |
| Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumor... NCT ID: NCT01638533 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Aveluma... NCT ID: NCT01772004 State: Multi-State Trial Investigator/Sponsoring Organization: EMD Serono |
Multi-State Trial | EMD Serono |
| LCCC 1209: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance I... NCT ID: NCT01655745 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program NCT ID: NCT01772771 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer NCT ID: NCT01840137 State: Michigan Investigator/Sponsoring Organization: University of Michigan |
Michigan | University of Michigan |
| Phase 2 Study Exploring the Efficacy and Safety of Neratinib Therapy in Patients With Solid Tumors ... NCT ID: NCT01953926 State: Multi-State Trial Investigator/Sponsoring Organization: Puma Biotechnology, Inc. |
Multi-State Trial | Puma Biotechnology, Inc. |
| A Randomized Trial of a Family Caregiver Palliative Care Intervention NCT ID: NCT01846520 State: California Investigator/Sponsoring Organization: City of Hope Medical Center |
California | City of Hope Medical Center |
| Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tol... NCT ID: NCT01976741 State: Multi-State Trial Investigator/Sponsoring Organization: Bayer |
Multi-State Trial | Bayer |
| Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer NCT ID: NCT01954173 State: Georgia Investigator/Sponsoring Organization: Emory University |
Georgia | Emory University |
| Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Ne... NCT ID: NCT02017509 State: Multi-State Trial Investigator/Sponsoring Organization: Providence Health & Services |
Multi-State Trial | Providence Health & Services |
| Integrated Cancer Repository for Cancer Research NCT ID: NCT02012699 State: Multi-State Trial Investigator/Sponsoring Organization: University of Nebraska |
Multi-State Trial | University of Nebraska |
| Intravenous CAVATAK™ (Coxsackievirus A21, CVA21) Alone and in Combination With Pembrolizumab in Pati... NCT ID: NCT02043665 State: Multi-State Trial Investigator/Sponsoring Organization: Viralytics |
Multi-State Trial | Viralytics |
| Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) NCT ID: NCT02080650 State: North Carolina Investigator/Sponsoring Organization: Duke University |
North Carolina | Duke University |
| Biomarker Identification for Bladder Cancer Patients NCT ID: NCT02053662 State: Ohio Investigator/Sponsoring Organization: Ohio State University Comprehensive Cancer Center |
Ohio | Ohio State University Comprehensive Cancer Center |
| Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (... NCT ID: NCT02141490 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle ... NCT ID: NCT02138734 State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience |
Multi-State Trial | Altor BioScience |
| Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery NCT ID: NCT02169284 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults... NCT ID: NCT02015104 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-mu... NCT ID: NCT02202772 State: New York Investigator/Sponsoring Organization: James M. McKiernan |
New York | James M. McKiernan |
| Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to C... NCT ID: NCT02170181 State: Texas Investigator/Sponsoring Organization: University of Texas Southwestern Medical Center |
Texas | University of Texas Southwestern Medical Center |
| Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Inv... NCT ID: NCT02177695 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Ta... NCT ID: NCT02223052 State: Multi-State Trial Investigator/Sponsoring Organization: Celgene |
Multi-State Trial | Celgene |
| Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improv... NCT ID: NCT02203136 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Phase II Trial of Estrogen Receptor Targeted Treatment of Non-Muscle Invasive Bladder Cancer With Ta... NCT ID: NCT02197897 State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine |
Multi-State Trial | Baylor College of Medicine |
| Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or... NCT ID: NCT02240238 State: Multi-State Trial Investigator/Sponsoring Organization: NanoCarrier Co., Ltd. |
Multi-State Trial | NanoCarrier Co., Ltd. |
| Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts NCT ID: NCT02246738 State: Pennsylvania Investigator/Sponsoring Organization: Abramson Cancer Center of the University of Pennsylvania |
Pennsylvania | Abramson Cancer Center of the University of Pennsylvania |
| Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study NCT ID: NCT02298998 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center at San Antonio |
Texas | The University of Texas Health Science Center at San Antonio |
| Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) fo... NCT ID: NCT02281383 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer NCT ID: NCT02300610 State: Multi-State Trial Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Multi-State Trial | H. Lee Moffitt Cancer Center and Research Institute |
| Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer NCT ID: NCT02324582 State: Multi-State Trial Investigator/Sponsoring Organization: Southern Illinois University |
Multi-State Trial | Southern Illinois University |
| Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors NCT ID: NCT02318329 State: Multi-State Trial Investigator/Sponsoring Organization: Five Prime Therapeutics, Inc. |
Multi-State Trial | Five Prime Therapeutics, Inc. |
| Evaluating Local and Regional Immune Responses to Intravesical BCG Administration to Patients With I... NCT ID: NCT02365207 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center at San Antonio |
Texas | The University of Texas Health Science Center at San Antonio |
| A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination Wit... NCT ID: NCT02315066 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-... NCT ID: NCT02365766 State: Multi-State Trial Investigator/Sponsoring Organization: Christopher Hoimes, M.D. |
Multi-State Trial | Christopher Hoimes, M.D. |
| Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens From Healthy Volunt... NCT ID: NCT02379429 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Determinants of Bladder Cancer Recurrence Study (The DETER Study) NCT ID: NCT02400944 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension ... NCT ID: NCT02420847 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Study of a p53MVA Vaccine in Combination With Pembrolizumab NCT ID: NCT02432963 State: California Investigator/Sponsoring Organization: City of Hope Medical Center |
California | City of Hope Medical Center |
| Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer NCT ID: NCT02437370 State: California Investigator/Sponsoring Organization: University of California, Davis |
California | University of California, Davis |
| Prevention of Parastomal Hernia Following Radical Cystectomy and Ileal Conduit Using Biologic Mesh: ... NCT ID: NCT02439060 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metast... NCT ID: NCT02443324 State: Multi-State Trial Investigator/Sponsoring Organization: Eli Lilly and Company |
Multi-State Trial | Eli Lilly and Company |
| Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy NCT ID: NCT02459119 State: Multi-State Trial Investigator/Sponsoring Organization: University of Alabama at Birmingham |
Multi-State Trial | University of Alabama at Birmingham |
| Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcino... NCT ID: NCT02451423 State: California Investigator/Sponsoring Organization: University of California, San Francisco |
California | University of California, San Francisco |
| Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscl... NCT ID: NCT02449239 State: Multi-State Trial Investigator/Sponsoring Organization: Viventia Bio |
Multi-State Trial | Viventia Bio |
| Ultrasound and Biomarker Tests of Bladder Cancer Invasiveness NCT ID: NCT02494635 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi... NCT ID: NCT02496208 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Met... NCT ID: NCT02500121 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment ... NCT ID: NCT02546661 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patient... NCT ID: NCT02552121 State: Multi-State Trial Investigator/Sponsoring Organization: Genmab |
Multi-State Trial | Genmab |
| Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patien... NCT ID: NCT02529553 State: Multi-State Trial Investigator/Sponsoring Organization: Eli Lilly and Company |
Multi-State Trial | Eli Lilly and Company |
| Study of Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients Wit... NCT ID: NCT02553642 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial ... NCT ID: NCT02567409 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of Curcumin and Piperine to Derive a Safe, Optimal Biologic Dose for Ureteral Stent-Induced Sy... NCT ID: NCT02598726 State: Minnesota Investigator/Sponsoring Organization: Mayo Clinic |
Minnesota | Mayo Clinic |
| Phase II Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Urothelial Cancer NCT ID: NCT02560038 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center, Houston |
Texas | The University of Texas Health Science Center, Houston |
| Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer NCT ID: NCT02612194 State: North Carolina Investigator/Sponsoring Organization: Earle Burgess |
North Carolina | Earle Burgess |
| Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination Wi... NCT ID: NCT02619253 State: Multi-State Trial Investigator/Sponsoring Organization: Roberto Pili |
Multi-State Trial | Roberto Pili |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladde... NCT ID: NCT02625961 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention NCT ID: NCT02605863 State: New York Investigator/Sponsoring Organization: University of Rochester |
New York | University of Rochester |
| Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-A... NCT ID: NCT02628535 State: Multi-State Trial Investigator/Sponsoring Organization: MacroGenics |
Multi-State Trial | MacroGenics |
| A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subje... NCT ID: NCT02632409 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Recep... NCT ID: NCT02643303 State: Multi-State Trial Investigator/Sponsoring Organization: Ludwig Institute for Cancer Research |
Multi-State Trial | Ludwig Institute for Cancer Research |
| A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers NCT ID: NCT02646319 State: Multi-State Trial Investigator/Sponsoring Organization: Mayo Clinic |
Multi-State Trial | Mayo Clinic |
| Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers NCT ID: NCT02648178 State: New Hampshire Investigator/Sponsoring Organization: Dartmouth-Hitchcock Medical Center |
New Hampshire | Dartmouth-Hitchcock Medical Center |
| Optional Sub-study to Intraoperative Imaging With ICG Registry NCT ID: NCT02651246 State: Pennsylvania Investigator/Sponsoring Organization: Abramson Cancer Center of the University of Pennsylvania |
Pennsylvania | Abramson Cancer Center of the University of Pennsylvania |
| Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystec... NCT ID: NCT02655081 State: Pennsylvania Investigator/Sponsoring Organization: University of Pittsburgh |
Pennsylvania | University of Pittsburgh |
| Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incu... NCT ID: NCT02655822 State: Multi-State Trial Investigator/Sponsoring Organization: Corvus Pharmaceuticals, Inc. |
Multi-State Trial | Corvus Pharmaceuticals, Inc. |
| Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder NCT ID: NCT02657486 State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
New York | Memorial Sloan Kettering Cancer Center |
| A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers NCT ID: NCT02675829 State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
New York | Memorial Sloan Kettering Cancer Center |
| Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystec... NCT ID: NCT02690558 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in ... NCT ID: NCT02693717 State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Multi-State Trial | M.D. Anderson Cancer Center |
| Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately A... NCT ID: NCT02695771 State: Multi-State Trial Investigator/Sponsoring Organization: Spectrum Health Hospitals |
Multi-State Trial | Spectrum Health Hospitals |
| Risk of Bladder Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Expo... NCT ID: NCT02695121 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Prospective Randomized Comparison of Robotic Versus Open Radical Cystectomy NCT ID: NCT02699853 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| Observation Versus Immediate Surgery of Low Risk Bladder Cancer NCT ID: NCT02700724 State: Tennessee Investigator/Sponsoring Organization: Vanderbilt University Medical Center |
Tennessee | Vanderbilt University Medical Center |
| Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced or Recurrent... NCT ID: NCT02710396 State: Multi-State Trial Investigator/Sponsoring Organization: Naiyer Rizvi |
Multi-State Trial | Naiyer Rizvi |
| Trimodality Bladder Preservation Therapy: Maximal Transurethral Resection Followed by Accelerated Me... NCT ID: NCT02710734 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Met... NCT ID: NCT02717156 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Inv... NCT ID: NCT02716623 State: Multi-State Trial Investigator/Sponsoring Organization: University of Kansas Medical Center |
Multi-State Trial | University of Kansas Medical Center |
| Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder NCT ID: NCT02745301 State: Tennessee Investigator/Sponsoring Organization: Vanderbilt University |
Tennessee | Vanderbilt University |
| Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Mu... NCT ID: NCT02722538 State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC |
Multi-State Trial | Taris Biomedical LLC |
| A Pilot Study to Test Rapid Acquisition of Point of Care Ultrasound for Various Applications NCT ID: NCT02831556 State: North Carolina Investigator/Sponsoring Organization: Duke University |
North Carolina | Duke University |
| A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients Wit... NCT ID: NCT02576665 State: Multi-State Trial Investigator/Sponsoring Organization: Tocagen Inc. |
Multi-State Trial | Tocagen Inc. |
| A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers NCT ID: NCT02767921 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements ... NCT ID: NCT02355886 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| Assessing Near Infrared Fluorescence Imaging Medical Technology for the Detection of Bladder Cancer NCT ID: NCT03058705 State: New York Investigator/Sponsoring Organization: Edward Messing |
New York | Edward Messing |
| Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers NCT ID: NCT03413982 State: Kansas Investigator/Sponsoring Organization: University of Kansas Medical Center |
Kansas | University of Kansas Medical Center |
| A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Ag... NCT ID: NCT03454451 State: Multi-State Trial Investigator/Sponsoring Organization: Corvus Pharmaceuticals, Inc. |
Multi-State Trial | Corvus Pharmaceuticals, Inc. |
| Randomized Clinical Trial of Intra-corporal vs Extra-corporal Urinary Diversion After Robot Assisted... NCT ID: NCT03469362 State: Florida Investigator/Sponsoring Organization: University of Miami |
Florida | University of Miami |
| Molecular Analysis for Therapy Choice (MATCH) NCT ID: NCT02465060 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study Of Avelumab (msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Mai... NCT ID: NCT02603432 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-Interferon (IFN)/Syn3) Administered I... NCT ID: NCT02773849 State: Multi-State Trial Investigator/Sponsoring Organization: FKD Therapies Oy |
Multi-State Trial | FKD Therapies Oy |
| STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-G... NCT ID: NCT02792192 State: Multi-State Trial Investigator/Sponsoring Organization: Hoffmann-La Roche |
Multi-State Trial | Hoffmann-La Roche |
| A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma NCT ID: NCT02788201 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-... NCT ID: NCT02808143 State: Illinois Investigator/Sponsoring Organization: Northwestern University |
Illinois | Northwestern University |
| Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Ch... NCT ID: NCT02807636 State: Multi-State Trial Investigator/Sponsoring Organization: Hoffmann-La Roche |
Multi-State Trial | Hoffmann-La Roche |
| Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Pa... NCT ID: NCT02812420 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry Optional Sub-Study I: ... NCT ID: NCT02852252 State: Pennsylvania Investigator/Sponsoring Organization: University of Pennsylvania |
Pennsylvania | University of Pennsylvania |
| Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Locali... NCT ID: NCT02885974 State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine |
Multi-State Trial | Baylor College of Medicine |
| Steps to Eliminate Postoperative Problems NCT ID: NCT02880176 State: Pennsylvania Investigator/Sponsoring Organization: University of Pennsylvania |
Pennsylvania | University of Pennsylvania |
| Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for t... NCT ID: NCT02887248 State: Multi-State Trial Investigator/Sponsoring Organization: SCRI Development Innovations, LLC |
Multi-State Trial | SCRI Development Innovations, LLC |
| Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Pati... NCT ID: NCT02891161 State: Multi-State Trial Investigator/Sponsoring Organization: Monika Joshi, MD |
Multi-State Trial | Monika Joshi, MD |
| A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malign... NCT ID: NCT02897375 State: Georgia Investigator/Sponsoring Organization: Emory University |
Georgia | Emory University |
| Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinom... NCT ID: NCT02897765 State: Multi-State Trial Investigator/Sponsoring Organization: Neon Therapeutics, Inc. |
Multi-State Trial | Neon Therapeutics, Inc. |
| A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) R... NCT ID: NCT02901548 State: Florida Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Florida | H. Lee Moffitt Cancer Center and Research Institute |
| A Prospective, Randomized Trial of Preventive Mesh Placement at the Time of Radical Cystectomy to Re... NCT ID: NCT02908061 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors NCT ID: NCT02834013 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Intravenous Lidocaine in the Perioperative Setting and the Effects on Postoperative Pain and Bowel F... NCT ID: NCT02924480 State: West Virginia Investigator/Sponsoring Organization: CAMC Health System |
West Virginia | CAMC Health System |
| Application-based Perioperative Management of the Radical Cystectomy Patient NCT ID: NCT02942121 State: Kansas Investigator/Sponsoring Organization: University of Kansas Medical Center |
Kansas | University of Kansas Medical Center |
| Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer NCT ID: NCT02957370 State: California Investigator/Sponsoring Organization: University of California, Irvine |
California | University of California, Irvine |
| MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT ID: NCT02964013 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladd... NCT ID: NCT02968732 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurr... NCT ID: NCT02969109 State: Minnesota Investigator/Sponsoring Organization: Genomic Health®, Inc. |
Minnesota | Genomic Health®, Inc. |
| A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite NCT ID: NCT02993900 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center |
Maryland | Sidney Kimmel Comprehensive Cancer Center |
| Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered M... NCT ID: NCT02989064 State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune |
Multi-State Trial | Adaptimmune |
| A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (M... NCT ID: NCT02989584 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evalua... NCT ID: NCT03039413 State: Pennsylvania Investigator/Sponsoring Organization: Sidney Kimmel Cancer Center at Thomas Jefferson University |
Pennsylvania | Sidney Kimmel Cancer Center at Thomas Jefferson University |
| Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patie... NCT ID: NCT03023319 State: Ohio Investigator/Sponsoring Organization: Nagla Karim |
Ohio | Nagla Karim |
| Functional Imaging of T-cell Activation With [18F]F-AraG in Bladder Cancer Patients Receiving Neoadj... NCT ID: NCT03007719 State: California Investigator/Sponsoring Organization: Lawrence Fong |
California | Lawrence Fong |
| Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer NCT ID: NCT03063125 State: Kansas Investigator/Sponsoring Organization: University of Kansas Medical Center |
Kansas | University of Kansas Medical Center |
| Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spa... NCT ID: NCT03063255 State: Florida Investigator/Sponsoring Organization: University of Florida |
Florida | University of Florida |
| Study To Evaluate Dna Methlyation Markers For Detection Of Primary Bladder Cancer In Urine Samples .... NCT ID: NCT03122964 State: Texas Investigator/Sponsoring Organization: MDx Health |
Texas | MDx Health |
| Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Uro... NCT ID: NCT03093922 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics,... NCT ID: NCT03125200 State: Multi-State Trial Investigator/Sponsoring Organization: ADC Therapeutics S.A. |
Multi-State Trial | ADC Therapeutics S.A. |
| Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer NCT ID: NCT03125460 State: Multi-State Trial Investigator/Sponsoring Organization: Cepheid |
Multi-State Trial | Cepheid |
| Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) NCT ID: NCT03133286 State: California Investigator/Sponsoring Organization: DxTerity Diagnostics |
California | DxTerity Diagnostics |
| Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity... NCT ID: NCT03132922 State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune |
Multi-State Trial | Adaptimmune |
| LCCC 1636: Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder C... NCT ID: NCT03156244 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer NCT ID: NCT03193515 State: Hawaii Investigator/Sponsoring Organization: University of Hawaii |
Hawaii | University of Hawaii |
| A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer NCT ID: NCT03193528 State: Hawaii Investigator/Sponsoring Organization: University of Hawaii |
Hawaii | University of Hawaii |
| St. Judes-Stanford Comprehensive Support Initiative NCT ID: NCT03154190 State: California Investigator/Sponsoring Organization: Stanford University |
California | Stanford University |
| ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer NCT ID: NCT03193541 State: Hawaii Investigator/Sponsoring Organization: University of Hawaii |
Hawaii | University of Hawaii |
| Measuring Surgical Recovery After Radical Cystectomy NCT ID: NCT03193970 State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Multi-State Trial | M.D. Anderson Cancer Center |
| MDSC Clinical Assay for Cancer Detection and Monitoring in Bladder Carcinoma NCT ID: NCT02735512 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| A Randomized Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive ... NCT ID: NCT02753309 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center at San Antonio |
Texas | The University of Texas Health Science Center at San Antonio |
| Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in P... NCT ID: NCT03250832 State: Multi-State Trial Investigator/Sponsoring Organization: Tesaro, Inc. |
Multi-State Trial | Tesaro, Inc. |
| Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Pat... NCT ID: NCT03224182 State: Wisconsin Investigator/Sponsoring Organization: Spectrum Pharmaceuticals, Inc |
Wisconsin | Spectrum Pharmaceuticals, Inc |
| TraceIT TM Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cance... NCT ID: NCT03125226 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multice... NCT ID: NCT02700464 State: Multi-State Trial Investigator/Sponsoring Organization: Nucleix Ltd. |
Multi-State Trial | Nucleix Ltd. |
| Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting ... NCT ID: NCT02153905 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer NCT ID: NCT02122172 State: Multi-State Trial Investigator/Sponsoring Organization: University of Chicago |
Multi-State Trial | University of Chicago |
| Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma NCT ID: NCT02793128 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery fo... NCT ID: NCT02412670 State: Multi-State Trial Investigator/Sponsoring Organization: ECOG-ACRIN Cancer Research Group |
Multi-State Trial | ECOG-ACRIN Cancer Research Group |
| Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in S... NCT ID: NCT02795156 State: Multi-State Trial Investigator/Sponsoring Organization: SCRI Development Innovations, LLC |
Multi-State Trial | SCRI Development Innovations, LLC |
| Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patient... NCT ID: NCT02688348 State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center |
California | Jonsson Comprehensive Cancer Center |
| UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Canc... NCT ID: NCT02643043 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Milowsky, MD |
Multi-State Trial | Matthew Milowsky, MD |
| Oral Supplementation to Enhance Recovery Pilot Study NCT ID: NCT03204266 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary ... NCT ID: NCT03134027 State: North Carolina Investigator/Sponsoring Organization: Duke University |
North Carolina | Duke University |
| Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients U... NCT ID: NCT02145871 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in P... NCT ID: NCT03047213 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Leukocyte Telomere Length in Bladder Cancer Survivors: Diet and Exercise Trial NCT ID: NCT03286699 State: Pennsylvania Investigator/Sponsoring Organization: University of Pittsburgh |
Pennsylvania | University of Pittsburgh |
| A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures NCT ID: NCT03138967 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI. NCT ID: NCT00938145 State: Ohio Investigator/Sponsoring Organization: Ohio State University Comprehensive Cancer Center |
Ohio | Ohio State University Comprehensive Cancer Center |
| Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach NCT ID: NCT00848289 State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Multi-State Trial | M.D. Anderson Cancer Center |
| A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized ... NCT ID: NCT03171025 State: Utah Investigator/Sponsoring Organization: University of Utah |
Utah | University of Utah |
| Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, an... NCT ID: NCT02900248 State: Idaho Investigator/Sponsoring Organization: CureOne |
Idaho | CureOne |
| Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Com... NCT ID: NCT02145390 State: Florida Investigator/Sponsoring Organization: University of Miami |
Florida | University of Miami |
| QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combinat... NCT ID: NCT03022825 State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience |
Multi-State Trial | Altor BioScience |
| A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 B... NCT ID: NCT03229278 State: New Jersey Investigator/Sponsoring Organization: Rutgers, The State University of New Jersey |
New Jersey | Rutgers, The State University of New Jersey |
| Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Sub... NCT ID: NCT03258593 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in P... NCT ID: NCT03289962 State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc. |
Multi-State Trial | Genentech, Inc. |
| Evaluation of the Performance of a Disposable Cystoscope System for Direct Visualization of the Uret... NCT ID: NCT03331705 State: Nevada Investigator/Sponsoring Organization: UroSee Corporation |
Nevada | UroSee Corporation |
| A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or M... NCT ID: NCT03330561 State: Multi-State Trial Investigator/Sponsoring Organization: Pieris Pharmaceuticals, Inc. |
Multi-State Trial | Pieris Pharmaceuticals, Inc. |
| Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combi... NCT ID: NCT02903914 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation |
Multi-State Trial | Incyte Corporation |
| Novel FGFR3 Inhibitor (B-701) Combined With Atezolizumab in Subjects With Locally Advanced or Metast... NCT ID: NCT03123055 State: Multi-State Trial Investigator/Sponsoring Organization: BioClin Therapeutics, Inc. |
Multi-State Trial | BioClin Therapeutics, Inc. |
| Safety and Preliminary Efficacy of NKTR 214 and Anti-PD-L1 (Atezolizumab) in Patients With Locally A... NCT ID: NCT03138889 State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics |
Multi-State Trial | Nektar Therapeutics |
| A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patien... NCT ID: NCT03219333 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
| Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as... NCT ID: NCT02621151 State: Multi-State Trial Investigator/Sponsoring Organization: New York University School of Medicine |
Multi-State Trial | New York University School of Medicine |
| Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Lo... NCT ID: NCT02001623 State: Multi-State Trial Investigator/Sponsoring Organization: Genmab |
Multi-State Trial | Genmab |
| High Resolution Imaging for Early and Better Detection of Bladder Cancer NCT ID: NCT02340650 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center, Houston |
Texas | The University of Texas Health Science Center, Houston |
| Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Ma... NCT ID: NCT02554812 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAP... NCT ID: NCT03317158 State: Multi-State Trial Investigator/Sponsoring Organization: Noah Hahn, M.D. |
Multi-State Trial | Noah Hahn, M.D. |
| Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Imm... NCT ID: NCT03106610 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell P... NCT ID: NCT03091660 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| A Window of Opportunity Phase II Study of Pembrolizumab in Patients With Bladder Cancer Undergoing R... NCT ID: NCT03319745 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for... NCT ID: NCT03404791 State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC |
Multi-State Trial | Taris Biomedical LLC |
| Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disea... NCT ID: NCT00026884 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients With Advanced Solid Mal... NCT ID: NCT02922764 State: Multi-State Trial Investigator/Sponsoring Organization: Rgenix, Inc. |
Multi-State Trial | Rgenix, Inc. |
| Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patien... NCT ID: NCT03294304 State: Multi-State Trial Investigator/Sponsoring Organization: Masonic Cancer Center, University of Minnesota |
Multi-State Trial | Masonic Cancer Center, University of Minnesota |
| GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer NCT ID: NCT03179943 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kineti... NCT ID: NCT03291028 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carc... NCT ID: NCT03430895 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT ID: NCT03452774 State: New York Investigator/Sponsoring Organization: Massive Bio, Inc. |
New York | Massive Bio, Inc. |
| Study of SGN-2FF in Patients With Advanced Solid Tumors NCT ID: NCT02952989 State: Multi-State Trial Investigator/Sponsoring Organization: Seattle Genetics, Inc. |
Multi-State Trial | Seattle Genetics, Inc. |
| Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell... NCT ID: NCT03236935 State: Texas Investigator/Sponsoring Organization: Jorge G. Darcourt |
Texas | Jorge G. Darcourt |
| Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithel... NCT ID: NCT02636036 State: Multi-State Trial Investigator/Sponsoring Organization: PsiOxus Therapeutics Ltd |
Multi-State Trial | PsiOxus Therapeutics Ltd |
| A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Effica... NCT ID: NCT03459846 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial ... NCT ID: NCT03397394 State: Multi-State Trial Investigator/Sponsoring Organization: Clovis Oncology, Inc. |
Multi-State Trial | Clovis Oncology, Inc. |
| Blue Light Cystoscopy With Cysview® Registry NCT ID: NCT02660645 State: Multi-State Trial Investigator/Sponsoring Organization: Photocure |
Multi-State Trial | Photocure |
| A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors NCT ID: NCT03514121 State: Multi-State Trial Investigator/Sponsoring Organization: Five Prime Therapeutics, Inc. |
Multi-State Trial | Five Prime Therapeutics, Inc. |
| Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refracto... NCT ID: NCT02581982 State: North Carolina Investigator/Sponsoring Organization: Wake Forest University Health Sciences |
North Carolina | Wake Forest University Health Sciences |
| Psychometric Evaluation of a Patient-Reported Symptom Index for Non-Muscle Invasive Bladder Cancer: ... NCT ID: NCT03091764 State: Multi-State Trial Investigator/Sponsoring Organization: University of Sydney |
Multi-State Trial | University of Sydney |
| Circulating Tumor DNA Exposure in Peripheral Blood Using a Novel Process: A Feasibility Study NCT ID: NCT03517332 State: Multi-State Trial Investigator/Sponsoring Organization: Quantgene Inc. |
Multi-State Trial | Quantgene Inc. |
| A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimuma... NCT ID: NCT03520491 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Locali... NCT ID: NCT03421652 State: Michigan Investigator/Sponsoring Organization: Barbara Ann Karmanos Cancer Institute |
Michigan | Barbara Ann Karmanos Cancer Institute |
| Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanc... NCT ID: NCT03244384 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy... NCT ID: NCT03288545 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
| A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With... NCT ID: NCT03517488 State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc. |
Multi-State Trial | Xencor, Inc. |
| A Pilot Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or M... NCT ID: NCT03473730 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atez... NCT ID: NCT03473756 State: Multi-State Trial Investigator/Sponsoring Organization: Bayer |
Multi-State Trial | Bayer |
| A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With ... NCT ID: NCT03519256 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle In... NCT ID: NCT03081858 State: California Investigator/Sponsoring Organization: TesoRx Pharma, LLC |
California | TesoRx Pharma, LLC |
| A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasi... NCT ID: NCT03518320 State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC |
Multi-State Trial | Taris Biomedical LLC |
| A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of... NCT ID: NCT01968109 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer NCT ID: NCT02844816 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasi... NCT ID: NCT02845323 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Maryland | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive... NCT ID: NCT03504163 State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
New York | Memorial Sloan Kettering Cancer Center |
| Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or ... NCT ID: NCT02401542 State: Multi-State Trial Investigator/Sponsoring Organization: BioClin Therapeutics, Inc. |
Multi-State Trial | BioClin Therapeutics, Inc. |
| Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refr... NCT ID: NCT02009332 State: Multi-State Trial Investigator/Sponsoring Organization: Aadi, LLC |
Multi-State Trial | Aadi, LLC |
| A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epiderm... NCT ID: NCT03602079 State: Multi-State Trial Investigator/Sponsoring Organization: Klus Pharma Inc. |
Multi-State Trial | Klus Pharma Inc. |
| A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bl... NCT ID: NCT03609216 State: Multi-State Trial Investigator/Sponsoring Organization: Alliance for Clinical Trials in Oncology |
Multi-State Trial | Alliance for Clinical Trials in Oncology |
| A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Toler... NCT ID: NCT02030067 State: Multi-State Trial Investigator/Sponsoring Organization: Rexahn Pharmaceuticals, Inc. |
Multi-State Trial | Rexahn Pharmaceuticals, Inc. |
| Mass Spectrometry Detection of Drugs in Single Bladder Cancer Cells From Patients NCT ID: NCT03639090 State: Oklahoma Investigator/Sponsoring Organization: University of Oklahoma |
Oklahoma | University of Oklahoma |
| A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cel... NCT ID: NCT03515551 State: Pennsylvania Investigator/Sponsoring Organization: Immunocore Ltd |
Pennsylvania | Immunocore Ltd |
| A Phase 2, Open Label Study To Evaluate Safety And Clinical Activity Of Avelumab (Bavencio (Register... NCT ID: NCT03472560 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of G... NCT ID: NCT03633110 State: Multi-State Trial Investigator/Sponsoring Organization: Genocea Biosciences, Inc. |
Multi-State Trial | Genocea Biosciences, Inc. |
| Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial... NCT ID: NCT03171493 State: Minnesota Investigator/Sponsoring Organization: Vyriad, Inc. |
Minnesota | Vyriad, Inc. |
| A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patient... NCT ID: NCT03650348 State: Multi-State Trial Investigator/Sponsoring Organization: Pieris Pharmaceuticals, Inc. |
Multi-State Trial | Pieris Pharmaceuticals, Inc. |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors NCT ID: NCT03662204 State: Multi-State Trial Investigator/Sponsoring Organization: Exact Sciences Corporation |
Multi-State Trial | Exact Sciences Corporation |
| A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastati... NCT ID: NCT03606174 State: Multi-State Trial Investigator/Sponsoring Organization: Mirati Therapeutics Inc. |
Multi-State Trial | Mirati Therapeutics Inc. |
| A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bl... NCT ID: NCT03498196 State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine |
Multi-State Trial | Baylor College of Medicine |
| A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participa... NCT ID: NCT03634982 State: Multi-State Trial Investigator/Sponsoring Organization: Revolution Medicines, Inc. |
Multi-State Trial | Revolution Medicines, Inc. |
| Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial C... NCT ID: NCT03534804 State: Utah Investigator/Sponsoring Organization: University of Utah |
Utah | University of Utah |
| A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Che... NCT ID: NCT03693014 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer W... NCT ID: NCT03558087 State: New York Investigator/Sponsoring Organization: Matthew Galsky |
New York | Matthew Galsky |
| A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients W... NCT ID: NCT03628716 State: Multi-State Trial Investigator/Sponsoring Organization: Bavarian Nordic |
Multi-State Trial | Bavarian Nordic |
| A Phase 2b, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as a Chemoa... NCT ID: NCT03558503 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus ... NCT ID: NCT03661320 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab... NCT ID: NCT03682068 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/... NCT ID: NCT02091141 State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc. |
Multi-State Trial | Genentech, Inc. |
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects W... NCT ID: NCT03474107 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
